As policymakers consider imposing a Most Favored Nation (MFN) model for prescription drug pricing, it's important to understand the effects this approach could have on patients, innovation, and the broader healthcare system. The attached issue guide outlines why MFN—a form of socialist price controls—would do little to reduce out-of-pocket costs for Medicaid patients, while significantly disrupting America’s globally leading biopharmaceutical sector.
Read MoreIf passed, Pelosi’s Plan would warp the market, limit doctors’ choices, restrict patient care, threaten new-drug R&D, and – most frighteningly – jeopardize people’s health.
Read MoreOn June 26, The Mosaic Company (NYSE: MOS) announced that it had filed petitions with the US International Trade Commission (ITC) and the US Department of Commerce (DoC) requesting the imposition of countervailing duties (CVDs) on imports of phosphate from Morocco and Russia. Mosaic’s stock has, since that date, appreciated 230% as of the market close on Tuesday, January 19, with price increases following key events related to the investigation.
Read MoreThe U.S. International Trade Commission (ITC) announced on 29 June 2020 - more than six months ago - that it was initiating the preliminary phase of a countervailing duty investigation (CVD) on the imports of phosphate fertilizer from Morocco. That investigation was triggered by a petition from Mosaic Company, the largest phosphate fertilizer company in the U.S. historically enjoying nearly three-quarters of the U.S. market share.
Read MoreThe American Edge Project (AEP) is a coalition of organizations and companies – both small and large – dedicated to protecting and promoting American innovation for the long term and economic recovery in the near term.
Read More